If initial Phase II data bear out in larger trials, Isis Pharmaceuticals Inc. thinks ISIS-APOCIIIRx could alter the treatment landscape for hypertriglyceridemia much like statins did for hypercholesterolemia.

ISIS-APOCIIIRx is an antisense inhibitor of apolipoprotein C-III (APOCIII; APOC3), which regulates triglyceride clearance from blood. Elevated plasma levels of APOC3 are pro-atherogenic and closely correlate with hypertriglyceridemia.